

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **July 27, 2022**

SILICON LABORATORIES INC.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-29823
(Commission File Number)

74-2793174
(IRS Employer
Identification No.)

400 West Cesar Chavez, Austin, TX
(Address of Principal Executive Offices)

78701
(Zip Code)

Registrant's telephone number, including area code: **(512) 416-8500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|----------------------------------|--------------------------|--|
| Common Stock, \$0.0001 par value | SLAB | The NASDAQ Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934.

Item 2.02. Results of Operations and Financial Condition

On July 27 2022, Silicon Laboratories Inc. (“Silicon Laboratories”) issued a press release describing its results of operations for its fiscal quarter ended July 2, 2022. A copy of the press release is attached as Exhibit 99 to this report.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

[99](#) [Press Release of Silicon Laboratories Inc. dated July 27, 2022](#)

104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Use of Non-GAAP Financial Information

From time to time, Silicon Laboratories provides certain non-GAAP financial measures as additional information relating to its operating results. The non-GAAP financial measurements provided in the press release furnished herewith do not replace the presentation of Silicon Laboratories’ GAAP financial results. These additional measurements merely provide supplemental information to assist investors in analyzing Silicon Laboratories’ financial position and results of operations; however, these measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies.

Non-GAAP financial measures used by Silicon Laboratories include non-GAAP gross margin, non-GAAP research and development expense, non-GAAP selling, general and administrative expense, non-GAAP operating income, non-GAAP interest expense, non-GAAP tax expense, non-GAAP net income and non-GAAP diluted earnings per share. Silicon Laboratories has chosen to provide this information to investors because it believes that such supplemental information enables them to perform meaningful comparisons of past, present and future operating results, and as a means to highlight the results of core ongoing operations.

Non-GAAP financial measures are adjusted by the following items:

- *Stock compensation expense* – represents charges for employee stock awards issued under Silicon Laboratories’ stock-based compensation plans. Stock compensation expense is excluded from non-GAAP financial measures because it is a non-cash expense, and excluding such expense provides meaningful supplemental information regarding core ongoing operations.
 - *Intangible asset amortization* – primarily represents charges for the amortization of intangibles assets, such as core and developed technology, customer relationships and trademarks, acquired in connection with business combinations. Intangible asset amortization is excluded from non-GAAP financial measures because it is a non-cash expense, and excluding such expense provides meaningful supplemental information regarding core ongoing operations.
 - *Acquisition and disposition related items* – primarily including the following: charges for the fair value write-up associated with inventory acquired; adjustments to the fair value of acquisition-related contingent consideration; and acquisition-related costs of a business combination or disposition-related costs of a business divestiture, such as costs for attorneys, investment bankers, accountants and other third party service providers. Acquisition and disposition related items are excluded from non-GAAP financial measures because excluding such amounts provides meaningful supplemental information regarding core ongoing operations.
 - *Termination costs, impairments and fair value adjustments* – primarily include costs associated with certain employee terminations, asset impairments and fair value adjustments resulting from observable price changes. Termination costs, impairments and fair value adjustments are excluded from non-GAAP financial measures because excluding such amounts provides meaningful supplemental information regarding core ongoing operations.
-

- *Equity-method investment adjustments* – primarily include the Company’s proportionate share of gains and/or losses from investments accounted for by the equity method of accounting. Equity-method investment adjustments are excluded from non-GAAP financial measures because these generally are non-cash, non-operating activity during the period of adjustment, relate to activity in entities outside those of Silicon Labs, and excluding such expense/gain provides meaningful supplemental information regarding core operations.
- *Interest expense adjustments* – represents losses on the extinguishment of convertible debt and losses on the termination of interest rate swap agreements. Such amounts are excluded from non-GAAP financial measures because they are non-cash expenses and/or excluding such amounts provides meaningful supplemental information regarding core ongoing operations.
- *Income tax adjustments* – primarily include the following: the current and deferred income tax effects of the above non-GAAP adjustments; other indirect impacts of excluding stock-based compensation; and the income tax impact of certain intercompany license arrangements for technology acquired in business combinations. Income tax adjustments are excluded from non-GAAP financial measures because excluding such amounts provides meaningful supplemental information regarding core ongoing operations.

Pursuant to the requirements of Regulation G, we have provided in the press release furnished with this report a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. The information contained therein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Silicon Laboratories, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SILICON LABORATORIES INC.

July 27, 2022

Date

/s/ John C. Hollister

John C. Hollister
*Senior Vice President and
Chief Financial Officer
(Principal Financial Officer)*



Silicon Labs Grows Revenue 55% in Second Quarter 2022

IoT Leader Achieves Significant Revenue Growth in Industrial & Commercial and Home & Life Business Units

AUSTIN, Texas – July 27, 2022 – [Silicon Labs](#) (NASDAQ: SLAB), a leader in secure, intelligent wireless technology for a more connected world, reported robust financial results for the second quarter, which ended July 2, 2022. Revenue exceeded the top end of the guidance range at \$263 million, up 13% sequentially and 55% year-on-year.

“We continue to gain momentum, building on strong design win performance, a growing opportunity funnel and market share expansion despite the challenging macro environment. We delivered record revenue in the quarter and operating results ahead of model, driving strong EPS growth,” said Matt Johnson, President and Chief Executive Officer of Silicon Labs. “We just marked the one-year anniversary of becoming a pure-play IoT company, and we are more confident than ever in our ability to lead and scale in the large and growing IoT wireless market.”

Second Quarter Financial Highlights

- Revenue increased to \$263 million, up 13% sequentially and 55% year-on-year
- Industrial & Commercial revenue for the quarter was \$144 million, up 61% year-on-year
- Home & Life revenue for the quarter was \$119 million, up 49% year-on-year
- Gross margin of 62% was slightly favorable due to product mix in the quarter

Results on a GAAP basis:

- GAAP gross margin was 62%
- GAAP R&D expenses were \$84 million
- GAAP SG&A expenses were \$49 million
- GAAP operating income as a percentage of revenue was 12%
- GAAP diluted earnings per share were \$0.60

Results on a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, and certain other items as set forth in the reconciliation tables were as follows:

- Non-GAAP gross margin was 62%
 - Non-GAAP R&D expenses were \$68 million
 - Non-GAAP SG&A expenses were \$41 million
 - Non-GAAP operating income as a percentage of revenue was 21%
 - Non-GAAP diluted earnings per share were \$1.17
-

Business Highlights

- Announced a new Bluetooth Location Services solution using accurate, low-power Bluetooth devices to simplify Angle of Arrival (AoA) and Angle of Departure (AoD) location services. This new platform combines the industry-leading energy efficiency of Silicon Labs' BG22 system-in-a-package (SiP) modules and SoCs, which can operate for up to ten years on only a coin cell battery, with advanced software that can track assets, improve indoor navigation, and locate tags with sub-meter accuracy.
- Completed the buyback of \$350 million of the company's shares through the most recent open market repurchase program, resulting in the retirement of 2.5 million shares and bringing the year-to-date total for share repurchases to \$600 million, retiring a total of 4.3 million shares. Additionally, the company's board of directors has authorized a new \$250 million open market repurchase program of the company's common stock, through the end of 2023.
- Announced the appointment of Robert ("Bob") Conrad to the company's board of directors. Conrad brings nearly 40 years of experience in the semiconductor industry, most recently with NXP Semiconductors (NASDAQ: NXPI) as SVP of the Automotive Microcontrollers and Processors Business until his retirement in 2019. In addition, Bob brings significant experience driving strategic focus and successfully scaling businesses.
- William ("Bill") Wood announced he will not stand for reelection and will be retiring from the Silicon Labs board after 25 years of service. Bill joined the board of directors in 1997 and served as lead director from 2005-2021. His board tenure concludes at the 2023 annual meeting of stockholders.

"Bill Wood has been instrumental to Silicon Labs' success since the very beginning of our journey," said Johnson. "We're grateful for his leadership throughout the years and wish him the very best."

Business Outlook

The company expects third-quarter revenue to be in the range of \$265 to \$275 million. The company also estimates the following results:

On a GAAP basis:

- GAAP gross margin of approximately 60%
- GAAP operating expenses of approximately \$137 million
- GAAP effective tax rate of approximately 36%
- GAAP diluted earnings per share between \$0.49 to \$0.59

On a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, and certain other items as set forth in the reconciliation tables:

- Non-GAAP gross margin of approximately 60.5%
 - Non-GAAP operating expenses of approximately \$113 million
-

- Non-GAAP effective tax rate of approximately 26%
- Non-GAAP diluted earnings per share between \$1.08 to \$1.18

Earnings Webcast and Conference Call

Silicon Labs will host an earnings conference call to discuss the quarterly results and answer questions at 7:30 am CDT today. An audio webcast will be available on Silicon Labs' website (www.silabs.com) under [Investor Relations](#). In addition, the company will post an audio recording of the event at silabs.com/investors and make a replay available through August 3, 2022, online or by calling (877) 344-7529 (US) or (412) 317-0088 (international) and entering access code 2437694.

About Silicon Labs

Silicon Labs (NASDAQ: SLAB) is a leader in secure, intelligent wireless technology for a more connected world. Our integrated hardware and software platform, intuitive development tools, thriving ecosystem, and robust support make us an ideal long-term partner in building advanced industrial, commercial, home and life applications. We make it easy for developers to solve complex wireless challenges throughout the product lifecycle and get to market quickly with innovative solutions that transform industries, grow economies, and improve lives. silabs.com

Forward-Looking Statements

This press release contains forward-looking statements based on Silicon Labs' current expectations. The words "believe", "estimate", "expect", "intend", "anticipate", "plan", "project", "will", and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Silicon Labs and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: the timing and scope of share repurchases, and/or dividends; the impact of COVID-19 on the U.S. and global economy, including the restrictions on travel and transportation and other actions taken by governmental authorities and disruptions to the business of our customers or our global supply chain that have occurred or may occur in the future, the ongoing impact of COVID-19 on our employees and our ability to provide services to our customers and respond to their needs; risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs' distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs' business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest, including risks that demand and the supply chain may be adversely affected by military conflict (including between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally; debt-related risks; capital-raising risks; the competitive and cyclical nature of the semiconductor industry; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs' products and its networks and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. The level of share repurchases and/or dividends depends on market conditions and the level of other uses of cash. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. References in this press release to Silicon Labs shall mean Silicon Laboratories Inc.

Note to editors: Silicon Laboratories, Silicon Labs, the "S" symbol, and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.

CONTACT: Thomas Haws, Investor Relations Manager, (512) 416-8500, investor.relations@silabs.com

Silicon Laboratories Inc.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)

| | Three Months Ended | | Six Months Ended | |
|--|--------------------|------------------|------------------|------------------|
| | July 2, 2022 | July 3, 2021 | July 2, 2022 | July 3, 2021 |
| Revenues | \$ 263,150 | \$ 169,492 | \$ 496,964 | \$ 327,349 |
| Cost of revenues | 99,247 | 73,194 | 177,289 | 139,297 |
| Gross profit | 163,903 | 96,298 | 319,675 | 188,052 |
| Operating expenses: | | | | |
| Research and development | 83,511 | 64,832 | 161,053 | 128,847 |
| Selling, general and administrative | 49,013 | 42,953 | 93,660 | 85,407 |
| Operating expenses | 132,524 | 107,785 | 254,713 | 214,254 |
| Operating income (loss) | 31,379 | (11,487) | 64,962 | (26,202) |
| Other income (expense): | | | | |
| Interest income and other, net | 3,445 | 475 | 4,944 | 1,624 |
| Interest expense | (1,667) | (6,486) | (3,347) | (17,810) |
| Income (loss) from continuing operations before income taxes | 33,157 | (17,498) | 66,559 | (42,388) |
| Provision for income taxes | 10,994 | 1,165 | 22,683 | 3,157 |
| Equity-method earnings | (28) | 172 | 1,166 | 1,898 |
| Income (loss) from continuing operations | 22,135 | (18,491) | 45,042 | (43,647) |
| Income from discontinued operations, net of income taxes | -- | 38,423 | -- | 77,088 |
| Net income | <u>\$ 22,135</u> | <u>\$ 19,932</u> | <u>\$ 45,042</u> | <u>\$ 33,441</u> |
| Basic earnings (loss) per share: | | | | |
| Continuing operations | \$ 0.62 | \$ (0.41) | \$ 1.22 | \$ (0.98) |
| Net income | \$ 0.62 | \$ 0.44 | \$ 1.22 | \$ 0.75 |
| Diluted earnings (loss) per share: | | | | |
| Continuing operations | \$ 0.60 | \$ (0.41) | \$ 1.18 | \$ (0.98) |
| Net income | \$ 0.60 | \$ 0.44 | \$ 1.18 | \$ 0.73 |
| Weighted-average common shares outstanding: | | | | |
| Basic | 35,722 | 44,803 | 36,862 | 44,481 |
| Diluted | 36,604 | 45,756 | 38,063 | 45,794 |

Non-GAAP Financial Measurements

In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.

The non-GAAP financial measurements do not replace the presentation of Silicon Labs' GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs' financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.

Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data)

| <u>Non-GAAP Income Statement Items</u> | <u>Three Months Ended July 2, 2022</u> | | | | | |
|--|--|--|---|--|----------------------------------|--|
| | <u>GAAP Measure</u> | <u>GAAP Percent of Revenue</u> | <u>Stock Compensation Expense</u> | <u>Intangible Asset Amortization</u> | <u>Non- GAAP Measure</u> | <u>Non-GAAP Percent of Revenue</u> |
| Revenues | \$ 263,150 | | | | | |
| Gross profit | 163,903 | 62.3% | \$ 274 | \$ -- | \$ 164,177 | 62.4% |
| Research and development | 83,511 | 31.7% | 7,703 | 7,363 | 68,445 | 26.0% |
| Selling, general and administrative | 49,013 | 18.7% | 6,412 | 1,479 | 41,122 | 15.6% |
| Operating income | 31,379 | 11.9% | 14,389 | 8,842 | 54,610 | 20.8% |

| <u>Non-GAAP Earnings Per Share</u> | <u>Three Months Ended July 2, 2022</u> | | | | | |
|------------------------------------|--|--|---|--|---------------------------------------|----------------------------------|
| | <u>GAAP Measure</u> | <u>Stock Compensation Expense*</u> | <u>Intangible Asset Amortization*</u> | <u>Equity-Method Investment Adjustments*</u> | <u>Income Tax Adjustments</u> | <u>Non- GAAP Measure</u> |
| Net income | \$ 22,135 | \$ 14,389 | \$ 8,842 | \$ 28 | \$ (2,631) | \$ 42,763 |
| Diluted shares outstanding | 36,604 | | | | | 36,604 |
| Diluted earnings per share | \$ 0.60 | | | | | \$ 1.17 |

* Represents pre-tax amounts

Unaudited Forward-Looking Statements Regarding Business Outlook
(In millions, except per share data)

| Business Outlook | Three Months Ending October 1, 2022 | | |
|-----------------------------------|--|----------------------------------|-----------------------------|
| | GAAP Measure | Non-GAAP Adjustments* | Non-GAAP Measure |
| Gross margin | 60% | 0.5% | 60.5% |
| Operating expenses | \$ 137 | \$ (24) | \$ 113 |
| Effective tax rate | 36% | (10)% | 26% |
| Diluted earnings per share - low | \$ 0.49 | \$ 0.59 | \$ 1.08 |
| Diluted earnings per share - high | \$ 0.59 | \$ 0.59 | \$ 1.18 |

* Non-GAAP adjustments include the following estimates: stock compensation expense of \$16.3 million, intangible asset amortization of \$8.1 million and the associated tax impact from the aforementioned items.

Silicon Laboratories Inc.
Condensed Consolidated Balance Sheets
(In thousands, except per share data)
(Unaudited)

| | July 2, 2022 | January 1, 2022 |
|---|---------------------|---------------------|
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 504,850 | \$ 1,074,623 |
| Short-term investments | 972,845 | 964,582 |
| Accounts receivable, net | 72,106 | 98,313 |
| Inventories | 74,026 | 49,307 |
| Prepaid expenses and other current assets | 86,138 | 51,748 |
| Total current assets | 1,709,965 | 2,238,573 |
| Property and equipment, net | 149,447 | 146,516 |
| Goodwill | 376,389 | 376,389 |
| Other intangible assets, net | 99,784 | 118,978 |
| Other assets, net | 83,813 | 77,839 |
| Total assets | <u>\$ 2,419,398</u> | <u>\$ 2,958,295</u> |
| Liabilities and Stockholders' Equity | | |
| Current liabilities: | | |
| Accounts payable | \$ 95,365 | \$ 47,327 |
| Current portion of convertible debt, net | -- | 450,599 |
| Deferred revenue and returns liability | 10,696 | 13,849 |
| Other current liabilities | 126,058 | 157,052 |
| Total current liabilities | 232,119 | 668,827 |
| Convertible debt, net | 528,564 | -- |
| Other non-current liabilities | 53,371 | 77,044 |
| Total liabilities | 814,054 | 745,871 |
| Commitments and contingencies | | |
| Stockholders' equity: | | |
| Preferred stock – \$0.0001 par value; 10,000 shares authorized; no shares issued | -- | -- |
| Common stock – \$0.0001 par value; 250,000 shares authorized; 34,223 and 38,481 shares issued and outstanding at July 2, 2022 and January 1, 2022, respectively | 3 | 4 |
| Retained earnings | 1,619,396 | 2,214,839 |
| Accumulated other comprehensive loss | (14,055) | (2,419) |
| Total stockholders' equity | 1,605,344 | 2,212,424 |
| Total liabilities and stockholders' equity | <u>\$ 2,419,398</u> | <u>\$ 2,958,295</u> |

Silicon Laboratories Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

| | Six Months Ended | |
|--|-------------------------|-------------------------|
| | July 2, 2022 | July 3, 2021 |
| Operating Activities | | |
| Net income | \$ 45,042 | \$ 33,441 |
| Adjustments to reconcile net income to cash provided by operating activities of continuing operations: | | |
| Income from discontinued operations, net of income taxes | -- | (77,088) |
| Depreciation of property and equipment | 10,561 | 8,184 |
| Amortization of other intangible assets | 19,194 | 22,902 |
| Amortization of debt discount and debt issuance costs | 994 | 11,822 |
| Loss on extinguishment of convertible debt | 3 | 3,370 |
| Stock-based compensation expense | 27,264 | 22,620 |
| Equity-method earnings | (1,166) | (1,898) |
| Deferred income taxes | (9,344) | (5,644) |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | 26,207 | (4,377) |
| Inventories | (24,714) | (4,447) |
| Prepaid expenses and other assets | (25,286) | (3,591) |
| Accounts payable | 25,606 | 14,711 |
| Other current liabilities and income taxes | (3,418) | (10,626) |
| Deferred revenue and returns liability | (3,153) | (175) |
| Other non-current liabilities | (4,416) | (3,464) |
| Net cash provided by operating activities of continuing operations | 83,374 | 5,740 |
| Investing Activities | | |
| Purchases of marketable securities | (554,267) | (80,426) |
| Sales of marketable securities | 27,404 | 186,626 |
| Maturities of marketable securities | 511,296 | 100,023 |
| Purchases of property and equipment | (12,322) | (10,779) |
| Purchases of other assets | -- | (578) |
| Net cash provided by (used in) investing activities of continuing operations | (27,889) | 194,866 |
| Financing Activities | | |
| Payments on debt | (21) | (140,572) |
| Repurchases of common stock | (579,040) | (18,982) |
| Payment of taxes withheld for vested stock awards | (13,958) | (19,732) |
| Proceeds from the issuance of common stock | 6,365 | 8,388 |
| Net cash used in financing activities of continuing operations | (586,654) | (170,898) |
| Discontinued Operations | | |
| Operating activities | (38,604) | 72,674 |
| Investing activities | -- | (2,018) |
| Net cash provided by (used in) discontinued operations | (38,604) | 70,656 |
| Increase (decrease) in cash and cash equivalents | (569,773) | 100,364 |
| Cash and cash equivalents at beginning of period | 1,074,623 | 202,720 |
| Cash and cash equivalents at end of period | <u>\$ 504,850</u> | <u>\$ 303,084</u> |